title: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
abstract: BACKGROUND
  The efficacy of new antihypertensive drugs has been questioned. We compared the effects of conventional and newer antihypertensive drugs on cardiovascular mortality and morbidity in elderly patients.
  
  
  METHODS
  We did a prospective, randomised trial in 6614 patients aged 70-84 years with hypertension (blood pressure > or = 180 mm Hg systolic, > or = 105 mm Hg diastolic, or both). Patients were randomly assigned conventional antihypertensive drugs (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily) or newer drugs (enalapril 10 mg or lisinopril 10 mg, or felodipine 2.5 mg or isradipine 2-5 mg daily). We assessed fatal stroke, fatal myocardial infarction, and other fatal cardiovascular disease. Analysis was by intention to treat.
  
  
  RESULTS
  Blood pressure was decreased similarly in all treatment groups. The primary combined endpoint of fatal stroke, fatal myocardial infarction, and other fatal cardiovascular disease occurred in 221 of 2213 patients in the conventional drugs group (19.8 events per 1000 patient-years) and in 438 of 4401 in the newer drugs group (19.8 per 1000; relative risk 0.99 [95% CI 0.84-1.16], p=0.89). The combined endpoint of fatal and non-fatal stroke, fatal and non-fatal myocardial infarction, and other cardiovascular mortality occurred in 460 patients taking conventional drugs and in 887 taking newer drugs (0.96 [0.86-1.08], p=0.49).
  
  
  CONCLUSIONS
  Old and new antihypertensive drugs were similar in prevention of cardiovascular mortality or major events. Decrease in blood pressure was of major importance for the prevention of cardiovascular events.
authors.affiliation: Department of Public Health and Social Sciences, University of Uppsala, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Hansson
authors.forename: L H
authors.initials: LH
authors.lastname: Lindholm
authors.forename: T
authors.initials: T
authors.lastname: Ekbom
authors.forename: B
authors.initials: B
authors.lastname: Dahlöf
authors.forename: J
authors.initials: J
authors.lastname: Lanke
authors.forename: B
authors.initials: B
authors.lastname: Scherstén
authors.forename: P O
authors.initials: PO
authors.lastname: Wester
authors.forename: T
authors.initials: T
authors.lastname: Hedner
authors.forename: U
authors.initials: U
authors.lastname: de Faire
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D011446:Prospective Studies; D012044:Regression Analysis; D012306:Risk; D020521:Stroke / Q000401:mortality / Q000517:prevention & control; D013548:Sweden / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents